The IMPACT of Anti-Phospholipid Antibodies on Severe Adverse Pregnancy Outcomes

Host: Dr. John Kingdom

Ontario Telemedicine Network (OTN) Live Video Feed

Locations
Mount Sinai Hospital
St. Michael’s Hospital
Sunnybrook Health Sciences Centre
North York General Hospital
St. Joseph’s Health Centre
Michael Garron Hospital
Trillium Health Partners – CVH
Trillium Health Partners – Mississauga
Humber River Hospital
Southlake Regional Health Care
Women’s College Hospital

OTN Live Webcast Watch Live: http://webcast.otn.ca/mywebcast?id=110994192

This is an open access/public event.

Live Q and A Session
Email questions during the event to: John.Kingdom@SinaiHealthSystem.ca

Ways to participate
- Live audience
- Live OTN video feed
- Live webcast (individual/group)
- Recorded - view web archive http://webcast.otn.ca/index/browse/?page=1&type=1 (password required for private gallery; search for "Interhospital" in the public events section)

Event Code: 110994192

To join the IHRounds network of clinical sites or receive IHR event alerts from UofT Ob/Gyn contact, obgyn.communications@utoronto.ca

Dr. A. Kinga Malinowski completed her fellowship in Maternal-Fetal Medicine at Mount Sinai Hospital, Toronto. Since joining the Maternal-Fetal Medicine Division at Mount Sinai Hospital in 2011, her clinical activity has focused on haematologic conditions affecting pregnancy. She is Co-Director of the Hematology in Pregnancy Program. Dr. Malinowski also holds the position of Clinician Investigator at Mount Sinai Hospital and the Lunenfeld-Tanenbaum Research Institute, with a cross-appointment at the rank of Assistant Professor at the University of Toronto. Thematically, her research interests parallel her clinical focus, with an emphasis on haematologic disorders in pregnancy, particularly as it relates to studies addressing the impact of Sickle Cell Disease on pregnancy outcomes. Concurrently, Dr. Malinowski has an interest in research standardization, pursuing the development of Core Outcome Sets for several haematologic disorders affecting pregnancy.

Dr. Carl Laskin has been at the University of Toronto in the Division of Rheumatology in the Department of Medicine since 1983. He was cross-appointed to the Department of Obstetrics & Gynecology in 1987. Subsequently he was appointed to the Division of Reproductive Endocrinology & Infertility. He is currently the Managing Director and Deputy Medical Director of TRIO Fertility in Toronto. Dr. Laskin continues to be actively involved in clinical research dealing with recurrent miscarriage; reproductive medicine in women and men with rheumatic diseases including infertility and pregnancy. Dr. Laskin is a past president of the Canadian Fertility & Andrology Society and will likely be the only rheumatologist to ever hold that office.

EDUCATIONAL OBJECTIVES

1) Identify clinical characteristics of anti-phospholipid syndrome (APS) in the pregnant and postpartum patient
2) Distinguish the relative significance of specific anti-phospholipid antibodies
3) Formulate an appropriate management plan for the patient with APS in pregnancy
4) Update your armamentarium in experimental treatment of APS in the pregnant woman with a past history of severe adverse medical or obstetrical outcome

Friday, February 22nd, 2019
7:45 A.M. - 8:45 A.M.
Mount Sinai Hospital, Ben Sadowski Auditorium, 18th Flr